Sage-Grouse Gets Federal Land Management Makeover
Published Date: 1/17/2025
Notice
Summary
The Bureau of Land Management just approved new plans to protect Greater Sage-Grouse habitats in Colorado and Oregon. These updates help wildlife and local communities by managing public lands better, with teamwork from 10 states and tribes. The changes start now, keeping things consistent across states without extra costs.
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
Rangewide RMP Updates Across 10 States
These RMP Amendments are part of a rangewide approach developed with 10 States, Tribes, local communities, and the public and update or will update goals, objectives, allocations, and management direction in 77 resource management plans. The listed States include California, Colorado, Idaho, Montana, Nevada, North Dakota, Oregon, South Dakota, Utah, and Wyoming.
RODs Approved for CO and OR
If you live in or use Bureau of Land Management (BLM) public lands in Colorado or Oregon, the BLM signed Records of Decision approving Resource Management Plan (RMP) Amendments for Greater Sage‑Grouse that are in effect upon signature. The decisions apply to Colorado and Oregon as part of the rangewide planning effort.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Related Federal Register Documents
2026-12299 — Presidential Declaration Amendment of a Major Disaster for Public Assistance Only for the Commonwealth of Kentucky
The President has updated the disaster declaration for Kentucky’s severe winter storm from January 23-27, 2026, adding Adair and Casey counties to the list of areas eligible for public assistance. This means more communities can get help recovering, with physical loan applications due by July 28, 2026, and economic injury loans available until March 1, 2027. If you’re in these counties, now’s the time to apply and get the support you need!
2026-12235 — Advisory Committee; Science Board to the Food and Drug Administration; Renewal
The FDA is renewing its Science Board for two more years, keeping expert advice flowing to help ensure safe and effective drugs and products. This renewal affects scientists and public health folks who guide the FDA’s big decisions, with the new term lasting until June 26, 2028. No extra costs or delays are expected—just more smart brains working for your health!
2026-12238 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Current Good Manufacturing Practice in Manufacturing, Packaging, Labeling, or Holding Operations for Dietary Supplements
The FDA is asking for public feedback by July 20, 2026, on their rules that keep dietary supplements safe and made right. These rules affect companies that make, package, label, or store supplements, helping ensure products are high quality without adding extra costs. This review keeps the safety standards up-to-date and clear for everyone involved.
2026-12241 — Agency Information Collection Activities: Submission for OMB Review; Comment Request
NARA wants to renew approval for a form that helps the FOIA Ombuds office get your okay before sharing info to solve Freedom of Information Act requests. This affects anyone asking for government records and means you might soon be able to submit consent forms online, making the process smoother. Comments on this plan are open until July 20, 2026, with no new costs involved.
2026-12285 — 737th Meeting of the Advisory Committee on Reactor Safeguards (ACRS)
The Advisory Committee on Reactor Safeguards (ACRS) is meeting July 8-10, 2026, to focus on updating how nuclear reactors get licensed and checked for safety. They’re trimming down their work to only the most important and new issues, thanks to a recent government order. This means faster, smarter reviews that affect nuclear plant operators and the public, with meetings open for remote participation and no big cost changes expected.
2026-12336 — PacifiCorp; Notice of Application Accepted for Filing, Intent To Waive Scoping, Soliciting Motions To Intervene and Protests, Ready for Environmental Analysis, and Soliciting Comments, Recommendations, and Terms and Conditions
PacifiCorp wants to keep running its Ashton Hydroelectric Project on the Snake River in Idaho without a full license, and the government is ready to review the environmental impact. Local communities, environmental groups, and energy users can share their thoughts or raise concerns by August 14, 2026. This move could speed up clean energy production while protecting the river, with decisions and replies wrapping up by late September.
Previous / Next Documents
Previous: 2025-01197 — Prevention and Treatment of Chemotherapy-Induced Peripheral Neuropathy: Developing Drug and Biological Products in Oncology; Draft Guidance for Industry; Availability
The FDA just dropped a draft guide to help drug makers create treatments that prevent or ease nerve pain caused by chemotherapy, a tough side effect that can mess with cancer care. This affects patients battling cancer and companies developing new drugs, aiming to keep treatments on track and improve lives. Comments on this guide are open until March 18, 2025, so get your thoughts in and help shape the final rules!
Next: 2025-01200 — Cell Therapies and Tissue-Based Products: A Public Workshop on Generating Scientific Evidence to Facilitate Development; Public Workshop; Request for Comments
The FDA is hosting a free online workshop on February 25, 2025, to talk about how to better develop and test cell therapies and tissue-based products, like stem cell treatments. This event is for scientists, companies, and anyone interested in making these medical products safer and more effective. People can join the conversation by sending their comments by March 18, 2025, helping shape the future of these exciting therapies.